论文部分内容阅读
目的探讨康妇消炎栓联合莫西沙星治疗盆腔炎(PID)后盆腔痛的效果。方法对北京大学第一医院等4家医院妇产科门诊的盆腔炎患者共70例,随机分组治疗。A组为单纯使用莫西沙星:符合静脉应用莫西沙星标准者,莫西沙星400mg,静滴,1次/d;好转后改为口服,莫西沙星400mg,1次/d,共14d。不符合静脉应用莫西沙星标准者,可直接口服。B组为康妇消炎栓联合莫西沙星:A组+康妇消炎栓,睡前肛用,一日1次,一次1枚。连用1个月。并连续随访3个月。结果治疗3d后,症状体征评分及评分改善比例分别为:A组6.78±5.22,(44.61±20.24)%、B组5.53±4.01,(48.68±28.22)%(P>0.05)。治疗30d症状体征评分及评分改善比例分别为:A组36.50,(78.97±17.75)%、B组34.66,(78.66±19.95)%(P>0.05)。治疗60d症状体征评分及评分改善比例分别为:A组34.50,(86.48±13.56)%、B组32.61,(85.49±16.51)%(P>0.05)。治疗90d症状体征评分及评分改善比例分别为:A组22.63,(87.47±11.42)%、B组13.88,(96.82±7.22)%,差异有统计学意义(症状体征评分:Z=-2.687,P=0.007;评分改善:F=-2.895,P=0.007)。结论在治疗PID的同时应用康妇消炎栓,有较好的预防盆腔炎的主要后遗症—盆腔痛的发生的作用。
Objective To investigate the effect of Kangfu anti-inflammatory suppository combined with moxifloxacin on pelvic pain after pelvic inflammatory disease (PID). Methods A total of 70 patients with pelvic inflammatory disease from 4 hospitals in Peking University First Hospital were randomly divided into treatment group and treatment group. A group of simple use of moxifloxacin: in line with intravenous moxifloxacin standard, moxifloxacin 400mg, intravenous infusion, 1 / d; improved to oral, moxifloxacin 400mg, 1 / d, a total of 14d. Do not meet the standard intravenous moxifloxacin, can be directly oral. B group of Kang Fu anti-inflammatory suppository combined with moxifloxacin: A group Kangxian anti-inflammatory suppository, anal bedtime, once a day, once a. Used for 1 month. And followed up for 3 months. Results After 3 days of treatment, the scores of symptom and symptom score and the scores of improvement were 6.78 ± 5.22 and 44.61 ± 20.24% respectively in group A and 5.53 ± 4.01 and 48.68 ± 28.22% respectively in group B (P> 0.05). The scores of symptom and symptom improvement on 30th day of treatment were 36.50 (78.97 ± 17.75)% in group A and 34.66 (78.66 ± 19.95)% in group B (P> 0.05) respectively. The scores of symptom and symptom scores on 60th day and the scores of improvement were 34.50 (86.48 ± 13.56)% in group A and 32.61 (85.49 ± 16.51)% in group B (P> 0.05) respectively. The score of symptom and symptom improvement at 90 days were 22.63 (87.47 ± 11.42)% in group A, 13.88 (96.82 ± 7.22)% in group B, the difference was statistically significant (symptom score: Z = -2.687, P = 0.007; score improvement: F = -2.895, P = 0.007). Conclusions In the treatment of PID with Kang Fu anti-inflammatory suppository, there is a better prevention of the main sequelae of pelvic inflammatory disease - the role of pelvic pain.